Vemurafenib
| Use attributes for filter ! | |
| Molar mass | 489. 92 g/mol |
|---|---|
| CAS ID | 1029872-54-5 |
| Other names | PLX4032, RG7204, RO5185426 |
| License data | EMA |
| US | |
| FDA | |
| Pronunciation | /ˌvɛməˈræfənɪb/ VEM-ə-RAF-ə-nib |
| ATC code | L01XE15 (WHO) |
| Music groups | Dabrafenib |
| Cobimetinib | |
| Trametinib | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951644 |
About Vemurafenib
Vemurafenib is an inhibitor of the B-Raf enzyme developed by Plexxikon and Genentech for the treatment of late-stage melanoma. The name "vemurafenib" comes from V600E mutated BRAF inhibition.